Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin versus vancomycin for MRSA-infected diabetic foot
2010-022348-18Phase 4Terminated
- Sponsor
- Heart and Diabetes Center North Rhine-Westphalia
- Start
- Sep 2010
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of daptomycin and vancomycin in diabetic foot infection (DFI) (2 arms), sponsored by Heart and Diabetes Center North Rhine-Westphalia. Primary endpoint: Clinical response at test-of-cure. Started Sep 2010; status: terminated.
02
Drugs
daptomycinvancomycin
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on 2010-022348-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022348-18.